Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
J. appl. oral sci ; 27: e20180316, 2019. tab
Artigo em Inglês | LILACS, BBO | ID: biblio-984569

RESUMO

Abstract Objective The aim of this study was to evaluate the levels of salivary biomarkers IL-1β, IL-10, RANK, OPG, MMP-2, TG-β and TNF-α in individuals with diagnosis of peri-implant mucositis in the absence or presence of periodontal and peri-implant maintenance therapy (TMPP) over 5 years. Material and Methods Eighty individuals diagnosed with peri-implant mucositis were divided into two groups: one group that underwent periodontal and peri-implant regularly maintenance therapy, called GTP (n=39), and a second group that received no regular maintenance GNTP (n=41). Each participant underwent a complete periodontal and peri-implant clinical examination. Collection of saliva samples and radiographic examination to evaluate peri-implant bone levels were conducted at two times: initial examination (T1) and after 5 years (T2). The salivary samples were evaluated through ELISA for the following markers: IL-1β, IL-10, RANK, OPG, MMP-2, TGF and TNF-α. Results A higher incidence of peri-implantitis was observed in the GNTP group (43.9%) than in the GTP group (18%) (p=0.000). All individuals (n=12) who presented peri-implant mucositis and had resolution at T2 were in the GTP group. After 5 years, there was an increase in the incidence of periodontitis in the GNTP group compared to the GTP group (p=0.001). The results of the study revealed an increase in the salivary concentration of TNF-α in the GNTP group compared to the GTP group. The other salivary biomarkers that were evaluated did not show statistically significant differences between the two groups. Conclusions The salivary concentration of TNF-α was increased in individuals with worse periodontal and peri-implant clinical condition and in those with a higher incidence of peri-implantitis, especially in the GNTP group. Longitudinal studies in larger populations are needed to confirm these findings and elucidate the role of this biomarker in peri-implant disease.


Assuntos
Humanos , Periodontite/patologia , Saliva/química , Estomatite/patologia , Implantes Dentários/efeitos adversos , Citocinas/análise , Receptor Ativador de Fator Nuclear kappa-B/análise , Osteoprotegerina/análise , Periodontite/diagnóstico , Valores de Referência , Estomatite/diagnóstico , Ensaio de Imunoadsorção Enzimática , Biomarcadores/análise , Estudos de Casos e Controles , Fatores de Risco , Seguimentos , Estatísticas não Paramétricas , Progressão da Doença
2.
J. appl. oral sci ; 27: e20180211, 2019. tab, graf
Artigo em Inglês | LILACS, BBO | ID: biblio-984568

RESUMO

Abstract Objective The aim of this study was to evaluate the effects of gliclazide on oxidative stress, inflammation, and bone loss in an experimental periodontal disease model. Material and Methods Male albino Wistar rats were divided into no ligature, ligature, and ligature with 1, 5, and 10 mg/kg gliclazide groups. Maxillae were fixed and scanned using micro-computed tomography to quantify linear and bone volume/tissue volume (BV/TV) and volumetric bone loss. Histopathological, immunohistochemical and immunofluorescence analyses were conducted to examine matrix metalloproteinase-2 (MMP-2), cyclooxygenase 2 (COX-2), cathepsin K, members of the receptor activator of the nuclear factor kappa-Β ligand (RANKL), receptor activator of nuclear factor kappa-Β (RANK), osteoprotegerin (OPG) pathway, macrophage migration inhibitory factor (MIF), superoxide dismutase-1 (SOD-1), glutathione peroxidase-1 (GPx-1), NFKB p 50 (Cytoplasm), NFKB p50 NLS (nuclear localization signal), PI3 kinase and AKT staining. Myeloperoxidase activity, malondialdehyde and glutathione levels, while interleukin-1 beta (IL-1β) and tumor necrosis factor-alpha (TNF-α) levels were evaluated by spectroscopic ultraviolet-visible analysis. A quantitative reverse transcription polymerase chain reaction was used to quantify the gene expression of the nuclear factor kappa B p50 subunit (NF-κB p50), phosphoinositide 3-kinase (PI3k), protein kinase B (AKT), and F4/80. Results Micro-computed tomography showed that the 1 mg/kg gliclazide treatment reduced linear bone loss compared to the ligature, 5 mg/kg gliclazide, and 10 mg/kg gliclazide treatments. All concentrations of gliclazide increased bone volume/tissue volume (BV/TV) compared to the ligature group. Treatment with 1 mg/kg gliclazide reduced myeloperoxidase activity, malondialdehyde, IL-1β, and TNF-α levels (p≤0.05), and resulted in weak staining for COX-2, cathepsin k, MMP-2, RANK, RANKL, SOD-1, GPx-1,MIF and PI3k. In addition, down-regulation of NF-κB p50, PI3k, AKT, and F4/80 were observed, and OPG staining was strong after the 1 mg/kg gliclazide treatment. Conclusions This treatment decreased neutrophil and macrophage migration, decreased the inflammatory response, and decreased bone loss in rats with ligature-induced periodontitis.


Assuntos
Animais , Masculino , Periodontite/tratamento farmacológico , Perda do Osso Alveolar/tratamento farmacológico , Estresse Oxidativo/efeitos dos fármacos , Gliclazida/farmacologia , Antioxidantes/farmacologia , Periodontite/patologia , Imuno-Histoquímica , Distribuição Aleatória , Reprodutibilidade dos Testes , Perda do Osso Alveolar/patologia , Imunofluorescência , Fatores Inibidores da Migração de Macrófagos/efeitos adversos , Fator de Necrose Tumoral alfa/análise , Ratos Wistar , Peroxidase/análise , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Metaloproteinase 2 da Matriz/análise , Interleucina-1beta/análise , Ligante RANK/análise , Receptor Ativador de Fator Nuclear kappa-B/análise , Microtomografia por Raio-X , Catepsina K/análise , Gengiva/patologia , Gengiva/química , Gliclazida/uso terapêutico , Glutationa/análise , Malondialdeído/análise , Neutrófilos/efeitos dos fármacos , Antioxidantes/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA